Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04509882
Other study ID # NCTNCT04002259
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 30, 2020
Est. completion date March 31, 2022

Study information

Verified date August 2020
Source Shanghai Mental Health Center
Contact Jing jing Huang
Phone +86 021 34773308
Email jjhuang_att@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in MDD patients conducted in Shang Hai Mental Health Center. The purpose of this study is to determine the efficacy and safety of bear bile pill in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy. Following a screening period, subjects who meet the entry criteria will be randomized to treated with either placebo or 450mg bear bile pill three times daily for 8 weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Meets the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition, Text Revision (DSM-V) criteria for Major Depressive Disorder (MDD); a single or recurrent episode without psychotic features ;Codes are as follows: F32.0?F32.1?F32.2?F33.0?F33.1 ?F33.2.

2. Outpatients or inpatients.

3. Male or female subjects aged 18-65 years.

4. Patients have got standard treatment of SSRI/SNRI monotherapy for more than 4 weeks in current episode of depression before trial entry.

5. MADRS score greater than 20.

6. Women of childbearing potential must be willing to use acceptable methods of contraception throughout the study period and the following one month.

7. The patient the patient fully understand and signed the informed consent form

Exclusion Criteria:

1. Patient has survived a suicide attempt or has acute suicidal tendencies (MADRS Item 10 > 4).

2. Comorbidity according to DSM-V, axis I except major depressive disorder.

3. Failed 3 or more adequate antidepressant courses in current episode of depression.

4. MADRS reduction ratio =25% within one week from the screening to the baseline Visit.

5. Depressive episode secondary to psychiatric illness or somatic disease.

6. Serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases.

7. History of alcohol or drug abuse over the last 6 months

8. Allergic history to bear bile pills, or serious drug allergic history.

9. Pregnant or lactating women and women of childbearing potential throughout the study period; men who have the desire of fertility within six months;

10. Clinically significant changes in ECG or laboratory tests, including >1.5X upper limit of normal liver function?over the limit of normal renal function and blood sugar?abnormal cardiac troponins?obvious abnormity in the thyroid function

11. Treatment with MECT or rTMS in nearly three months.

12. Treatment with a systematic psychological treatment in nearly three months.

Study Design


Intervention

Drug:
bear bile pill
Bear bile pill (15 pills) taken orally three times a day after meals with water.
placebo
Placebo(15 pills) taken orally three times a day after meals with water.

Locations

Country Name City State
China Jing jing Huang Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the total Montgomery-Asberg Depression Rating Scale (MADRS) score between randomization and end of study. The main objective is to explore whether bear bile pill add on SSRI or SNRI will improve the MDD symptoms after 8 weeks of treatment, and investigators assess the scale at baseline and week 1, 2, 4, 8. assessed from baseline to week 8(end of study)
Secondary Effective treatment effectivity:MADRS or HAMD reduction ratio =50% reductive ratio: [(Baseline score- Endpoint score)/Baseline score]×100% assessed from baseline to week 8 (end of study)
Secondary Clinical remission rate patients who are in remission at the end of the study will be summarized by treatment group, MADRS score =12 or HAMD-17=7. assessed from baseline to week 8 (end of study)
Secondary The Montgomery-Asberg Depression Rating Scale (MADRS) reduction ratio MADRS reduction ratio were used to evaluate the effectiveness of the treatment,and investigators assess the scale at baseline and week 1, 2, 4, 8. assessed from baseline to week 8 (end of study)
Secondary The Hamilton Depression Rating Scale (HAM-D17) reduction ratio the Hamilton Depression Rating Scale reduction ratio were used to evaluate the effectiveness of the treatment,and investigators assess the scale at baseline and week 1, 2, 4, 8. assessed from baseline to week 8 (end of study)
Secondary change in the total score of the Hamilton Anxiety Scale(HAMA) assessed from baseline to week 8 (end of study)
Secondary change in total score of the Clinical Global Impression-Severity (CGI-S) scale. assessed from baseline to week 8 (end of study)
Secondary change in total score of the Clinical Global Impression-Improvement (CGI-I) scale. assessed from baseline to week 8 (end of study)
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A